Sievers Eric 4

What Happened
Eric Sievers, Chief Medical Officer of BioAtla, was granted 240,000 restricted stock units (RSUs) on 2026-03-10. The award was reported as an acquisition (grant) at $0.00 per share (i.e., a compensatory equity award rather than a purchase). This is an equity grant, not a market purchase or sale.

Key Details

• Transaction date: 2026-03-10; filing date: 2026-03-12 (timely filed).
• Transaction type: Award/Grant of RSUs (code A on Form 4).
• Shares granted: 240,000 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: RSUs vest 25% on March 10, 2027, then 6.25% of the total shares vests on the last day of each May, August, November, and February thereafter, subject to continued service (i.e., completes over four years).
• No indication of a 10b5-1 plan, tax withholding sale, or immediate sale of shares in this filing.

Context
RSUs are a form of compensation that convert into shares only as they vest; they are not an immediate cash investment by the insider. This grant increases potential future ownership if Sievers remains employed through vesting dates. The filing is informational and does not, by itself, indicate buying or selling sentiment.